Record Information |
---|
Version | 1.0 |
---|
Creation Date | 2016-05-26 05:24:49 UTC |
---|
Update Date | 2016-11-09 01:21:13 UTC |
---|
Accession Number | CHEM035007 |
---|
Identification |
---|
Common Name | Farnesyl pyrophosphate |
---|
Class | Small Molecule |
---|
Description | |
---|
Contaminant Sources | |
---|
Contaminant Type | Not Available |
---|
Chemical Structure | |
---|
Synonyms | Value | Source |
---|
(2E,6E)-Farnesol diphosphate | ChEBI | (2E,6E)-Farnesyl diphosphate | ChEBI | (2E,6E)-Farnesyl pyrophosphate | ChEBI | (all-e)-Farnesyl diphosphate | ChEBI | (e,e)-Farnesyl pyrophosphate | ChEBI | 2-trans,6-trans-Farnesyl pyrophosphate | ChEBI | all-trans-Farnesyl pyrophosphate | ChEBI | Farnesyl diphosphate | ChEBI | trans,trans-Farnesyl diphosphate | ChEBI | trans-trans-Farnesyl diphosphate | ChEBI | 2-trans,6-trans-Farnesyl diphosphate | Kegg | (2E,6E)-Farnesol diphosphoric acid | Generator | (2E,6E)-Farnesyl diphosphoric acid | Generator | (2E,6E)-Farnesyl pyrophosphoric acid | Generator | (all-e)-Farnesyl diphosphoric acid | Generator | (e,e)-Farnesyl pyrophosphoric acid | Generator | 2-trans,6-trans-Farnesyl pyrophosphoric acid | Generator | all-trans-Farnesyl pyrophosphoric acid | Generator | Farnesyl diphosphoric acid | Generator | trans,trans-Farnesyl diphosphoric acid | Generator | trans-trans-Farnesyl diphosphoric acid | Generator | 2-trans,6-trans-Farnesyl diphosphoric acid | Generator | Farnesyl pyrophosphoric acid | Generator | (e,e)-Farnesyl diphosphate | HMDB | Farnesyl-PP | HMDB | trans-Farnesyl pyrophosphate | HMDB | trans-trans-Farnesyl pyrophosphate | HMDB | Farnesyl pyrophosphate, (e,e)-isomer | HMDB | Farnesyl pyrophosphate, (e,Z)-isomer | HMDB | Farnesyl pyrophosphate, (Z,e)-isomer | HMDB | Farnesyl pyrophosphate, (Z,Z)-isomer | HMDB | Farnesylpyrophosphate | HMDB |
|
---|
Chemical Formula | C15H28O7P2 |
---|
Average Molecular Mass | 382.330 g/mol |
---|
Monoisotopic Mass | 382.131 g/mol |
---|
CAS Registry Number | 372-97-4 |
---|
IUPAC Name | {[hydroxy({[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]oxy})phosphoryl]oxy}phosphonic acid |
---|
Traditional Name | farnesyl diphosphate |
---|
SMILES | [H]OP(=O)(O[H])OP(=O)(O[H])OC\C=C(/C)CC\C=C(/C)CCC=C(C)C |
---|
InChI Identifier | InChI=1S/C15H28O7P2/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-21-24(19,20)22-23(16,17)18/h7,9,11H,5-6,8,10,12H2,1-4H3,(H,19,20)(H2,16,17,18)/b14-9+,15-11+ |
---|
InChI Key | VWFJDQUYCIWHTN-YFVJMOTDSA-N |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as sesquiterpenoids. These are terpenes with three consecutive isoprene units. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Prenol lipids |
---|
Sub Class | Sesquiterpenoids |
---|
Direct Parent | Sesquiterpenoids |
---|
Alternative Parents | |
---|
Substituents | - Farsesane sesquiterpenoid
- Sesquiterpenoid
- Organic pyrophosphate
- Isoprenoid phosphate
- Monoalkyl phosphate
- Alkyl phosphate
- Phosphoric acid ester
- Organic phosphoric acid derivative
- Organic oxygen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Aliphatic acyclic compound
|
---|
Molecular Framework | Aliphatic acyclic compounds |
---|
External Descriptors | |
---|
Biological Properties |
---|
Status | Detected and Not Quantified |
---|
Origin | Not Available |
---|
Cellular Locations | Not Available |
---|
Biofluid Locations | Not Available |
---|
Tissue Locations | Not Available |
---|
Pathways | Not Available |
---|
Applications | Not Available |
---|
Biological Roles | Not Available |
---|
Chemical Roles | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Appearance | Not Available |
---|
Experimental Properties | Property | Value |
---|
Melting Point | Not Available | Boiling Point | Not Available | Solubility | Not Available |
|
---|
Predicted Properties | |
---|
Spectra |
---|
Spectra | Spectrum Type | Description | Splash Key | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | splash10-004j-7943000000-ab6d749700f510a94133 | Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - n/a 26V, negative | splash10-014i-0090000000-09efa5f4e481376eae3d | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - Orbitrap 11V, negative | splash10-001i-2009000000-b2358e50ee86b2ebccb5 | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - Orbitrap 14V, negative | splash10-004i-9004000000-b255d40b3beef0ddd16f | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - Orbitrap 16V, negative | splash10-004i-9001000000-64cd48aa93040d775977 | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - Orbitrap 19V, negative | splash10-004i-9000000000-84a4e8d938e03661128e | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - Orbitrap 25V, negative | splash10-004i-9000000000-eb2e768f7c19af669f74 | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - n/a 26V, negative | splash10-03di-0209000000-651c59dc3e732ea880d7 | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - n/a 26V, negative | splash10-0a4i-0900000000-ae4be9bde4ed56cfa99b | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - n/a 26V, positive | splash10-0002-0294000000-7019f71a6e4f542dddae | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-0pc0-1469000000-e3fd27c0418d0977f84e | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-0a4i-6791000000-1ca128d2b96287a5b2f1 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-0q29-9820000000-3277fbdf16e288ab1142 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-001i-0409000000-f8bbf786ee9d33cb48d4 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-004i-9501000000-8d060d3ceac94de45b8d | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-004i-9000000000-a265a369e6802359a7df | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-001i-0009000000-ea5bda9906940e9694b2 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-001i-2409000000-4b044bb59695723b85bd | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-056r-9600000000-a090357e0efeb6192936 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-001i-0019000000-66a0a5510c1d34aea230 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-114i-0394000000-89ab3170c9695823fb2f | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-05rs-6900000000-7b5163a81d3cbdf1feb4 | Spectrum | 1D NMR | 13C NMR Spectrum | Not Available | Spectrum | 1D NMR | 1H NMR Spectrum | Not Available | Spectrum | 1D NMR | 13C NMR Spectrum | Not Available | Spectrum | 1D NMR | 1H NMR Spectrum | Not Available | Spectrum | 1D NMR | 13C NMR Spectrum | Not Available | Spectrum | 1D NMR | 1H NMR Spectrum | Not Available | Spectrum | 1D NMR | 13C NMR Spectrum | Not Available | Spectrum | 1D NMR | 1H NMR Spectrum | Not Available | Spectrum | 1D NMR | 13C NMR Spectrum | Not Available | Spectrum | 1D NMR | 1H NMR Spectrum | Not Available | Spectrum | 1D NMR | 13C NMR Spectrum | Not Available | Spectrum | 1D NMR | 1H NMR Spectrum | Not Available | Spectrum | 1D NMR | 13C NMR Spectrum | Not Available | Spectrum | 1D NMR | 1H NMR Spectrum | Not Available | Spectrum | 1D NMR | 13C NMR Spectrum | Not Available | Spectrum | 1D NMR | 1H NMR Spectrum | Not Available | Spectrum | 1D NMR | 13C NMR Spectrum | Not Available | Spectrum | 1D NMR | 1H NMR Spectrum | Not Available | Spectrum | 1D NMR | 13C NMR Spectrum | Not Available | Spectrum | 1D NMR | 1H NMR Spectrum | Not Available | Spectrum |
|
---|
Toxicity Profile |
---|
Route of Exposure | Not Available |
---|
Mechanism of Toxicity | Not Available |
---|
Metabolism | Not Available |
---|
Toxicity Values | Not Available |
---|
Lethal Dose | Not Available |
---|
Carcinogenicity (IARC Classification) | Not Available |
---|
Uses/Sources | Not Available |
---|
Minimum Risk Level | Not Available |
---|
Health Effects | Not Available |
---|
Symptoms | Not Available |
---|
Treatment | Not Available |
---|
Concentrations |
---|
| Not Available |
---|
External Links |
---|
DrugBank ID | DB07780 |
---|
HMDB ID | HMDB0000961 |
---|
FooDB ID | FDB022339 |
---|
Phenol Explorer ID | Not Available |
---|
KNApSAcK ID | C00007268 |
---|
BiGG ID | 35006 |
---|
BioCyc ID | FARNESYL-PP |
---|
METLIN ID | 403 |
---|
PDB ID | Not Available |
---|
Wikipedia Link | Farnesyl pyrophosphate |
---|
Chemspider ID | 393270 |
---|
ChEBI ID | 17407 |
---|
PubChem Compound ID | 445713 |
---|
Kegg Compound ID | C00448 |
---|
YMDB ID | YMDB00229 |
---|
ECMDB ID | ECMDB00961 |
---|
References |
---|
Synthesis Reference | Not Available |
---|
MSDS | Not Available |
---|
General References | 1. Castillo-Bocanegra, Rafael. Synthesis and biological activity of farnesyl pyrophosphate analogs. University of California, San Francisco., 1977 - Farnesol p.364 | 2. Shellman YG, Ribble D, Miller L, Gendall J, Vanbuskirk K, Kelly D, Norris DA, Dellavalle RP: Lovastatin-induced apoptosis in human melanoma cell lines. Melanoma Res. 2005 Apr;15(2):83-9. | 3. Argmann CA, Edwards JY, Sawyez CG, O'Neil CH, Hegele RA, Pickering JG, Huff MW: Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. J Biol Chem. 2005 Jun 10;280(23):22212-21. Epub 2005 Apr 6. | 4. Reigard SA, Zahn TJ, Haworth KB, Hicks KA, Fierke CA, Gibbs RA: Interplay of isoprenoid and peptide substrate specificity in protein farnesyltransferase. Biochemistry. 2005 Aug 23;44(33):11214-23. | 5. Tacer KF, Haugen TB, Baltsen M, Debeljak N, Rozman D: Tissue-specific transcriptional regulation of the cholesterol biosynthetic pathway leads to accumulation of testis meiosis-activating sterol (T-MAS). J Lipid Res. 2002 Jan;43(1):82-9. | 6. Saisho Y, Morimoto A, Umeda T: Determination of farnesyl pyrophosphate in dog and human plasma by high-performance liquid chromatography with fluorescence detection. Anal Biochem. 1997 Oct 1;252(1):89-95. | 7. Sanders JM, Song Y, Chan JM, Zhang Y, Jennings S, Kosztowski T, Odeh S, Flessner R, Schwerdtfeger C, Kotsikorou E, Meints GA, Gomez AO, Gonzalez-Pacanowska D, Raker AM, Wang H, van Beek ER, Papapoulos SE, Morita CT, Oldfield E: Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption. J Med Chem. 2005 Apr 21;48(8):2957-63. | 8. Notarnicola M, Messa C, Cavallini A, Bifulco M, Tecce MF, Eletto D, Di Leo A, Montemurro S, Laezza C, Caruso MG: Higher farnesyl diphosphate synthase activity in human colorectal cancer inhibition of cellular apoptosis. Oncology. 2004;67(5-6):351-8. | 9. Fukuchi J, Song C, Ko AL, Liao S: Transcriptional regulation of farnesyl pyrophosphate synthase by liver X receptors. Steroids. 2003 Sep;68(7-8):685-91. | 10. https://www.ncbi.nlm.nih.gov/pubmed/?term=7753173 |
|
---|